Inhaled Cannabis Raises Propofol Needs for Upper Endoscopy by 27% Versus Non-Users
Retrospective data indicate inhaled but not edible cannabis increases propofol requirements during upper endoscopy, likely via airway effects. Small edible subgroup and lack of peer review limit immediate clinical translation. Route-stratified prospective trials are the logical next step.
The presentation does not alter current indications for endoscopy but underscores the need for route-specific history taking. Larger prospective studies with verified cannabis biomarkers and standardized sedation protocols are required before dose-adjustment algorithms can be validated or incorporated into guidelines.
Goudra et al.: Multicenter validation study will confirm at least 25% higher propofol dose requirement in chronic inhaled users during EGD within 24 months.
Sources (3)
- [1]Primary Source(https://www.asahq.org/education-and-events/annual-meeting)
- [2]Supporting Source(https://journals.lww.com/anesthesia/Abstract/2023/04000/Cannabis_Use_and_Propofol_Requirements_during.15.aspx)
- [3]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMra2204661)